EpilepsyGTx

To add a bio or update company history, please click update information.

News from EpilepsyGTx

$EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy$ $EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy$

EpilepsyGTx

10 Dec 2025

EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy

EpilepsyGTx develops gene therapies for severe epilepsy, aiming to stop seizures with a single targeted treatment rather than long-term medication.

EpilepsyGTx

Life Sciences
Cambridge, United Kingdom
£25m
epilepsygtx.com
Update Information

More venture news

Imperagen
21 May 2026
Imperagen secures a £5m seed round led by PXN Ventures to accelerate the process of enzyme engineering
SeedLife Sciences
Infex Therapeutic
12 May 2026
Infex Therapeutics secures £4.3m in funding led by Jon Moulton for antimicrobial resistance treatments
EquityLife Sciences
Scarlet Therapeutics
11 May 2026
Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases
SeedLife Sciences

EpilepsyGTx

News from EpilepsyGTx

EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy

More venture news

Imperagen secures a £5m seed round led by PXN Ventures to accelerate the process of enzyme engineering

Infex Therapeutics secures £4.3m in funding led by Jon Moulton for antimicrobial resistance treatments

Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases